


How Your Plasma Could Lead to a Potential Treatment for COVID-19

When you donate your plasma after recovering from COVID-19, you become the essential first step in a journey to develop a potential treatment for COVID-19. Even though no one can predict the results of clinical trials, here is a quick overview of the intended plan.



About the CoVIg-19 Plasma Alliance

In an effort to help fight against the COVID-19 pandemic, a new alliance was created in April 2020 to help develop a potential plasma-derived therapy for people at risk for serious complications from COVID-19.

The CoVIg-19 Plasma Alliance brings together world-leading plasma companies to work on the development of an investigational unbranded polyclonal anti-SARS-CoV-2 hyperimmune globulin medicine with the potential to treat patients who are at risk for serious complications from COVID-19.

The "I" and "g" in CoVIg-19 stand for immune globulin, which the CoVIg-19 Plasma Alliance will use to concentrate the antibodies into a potential medicine.

The Alliance, formed by CSL Behring and Takeda, also includes the leading-edge expertise of Biotest, BPL, LFB, and Octapharma. The Bill & Melinda Gates Foundation is providing advisory support. Microsoft is providing technology including the Alliance website and the Plasma Bot for donor recruitment. Experts from the Alliance are collaborating across key aspects such as plasma collection, clinical trial development, and product manufacturing.

